IL28B polymorphism, explanation for Different Responses to Therapy in Hepatitis C Patients

Hepatitis C infection is a major global public health problem (1). Treatment of hepatitis C with pegylated interferon α plus Ribavirin as a standard of care (SoC) for the management of this disease, leads to eradication of the virus in less than 60% of patients (2). Different sustained virological response (SVR) rates in different populations is a challenging fact that has been observed by researchers and inspired them to search for the causes (3).